Drug Trial Radar · NCT06440525
A Study of RSLV-132 in Females With Sjögren's Disease
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
106
Planned (sponsor's estimate)
Start
Dec 1, 2024
Primary completion
May 1, 2027
Study completion May 1, 2027
Sponsor
- Lead sponsor
- Resolve TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: * Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? * Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? * What are the blood levels of RSLV-132 over time? * What is the immune (antibody) response in the body to RSLV-132? * What is the safety profile of RSLV-132? Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS. Participants will: Take RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device
Conditions
- Primary Sjögren Syndrome
Interventions
RSLV-132Drug
Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
PlaceboDrug
0.9% sodium chloride solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of cardinal symptoms of Sjogren'sTime frame: Measured daily from at least 7 days prior to first dose until 169 days after the first dose
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Resolve Clinical Site
Chula Vista, California
Resolve Clinical Site
Tustin, California
Resolve Clinical Site
Boca Raton, Florida
Resolve Clinical Site
Boynton Beach, Florida
Evolution Research Center
Hialeah, Florida
GNP Research
Hollywood, Florida
Resolve Clinical Site
Miami, Florida
Life Medical Research
Miami Gardens, Florida
Resolve Clinical Site
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Tufts College
Boston, Massachusetts
Resolve Clinical Site
Albuquerque, New Mexico
Joint and Muscle Research Institute
Charlotte, North Carolina
Arthritis and Osteoporosis Consultants of the Carolinas
Charlotte, North Carolina
Onsite Clinical Solutions
Salisbury, North Carolina
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Resolve Clinical Site
Nashville, Tennessee
Resolve Clinical Site
Austin, Texas
Resolve Clinical Site
Katy, Texas
Resolve Clinical Site
McKinney, Texas
Accurate Clinical Research
Richmond, Texas
Resolve Clinical Site
San Antonio, Texas
Metrodora Institute
Salt Lake City, Utah
Arthritis Northwest
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.